(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

USO DE IRGD (CEND-1) E UMA CITOCINA PARA TRATAR, INIBIR OU REDUZIR O VOLUME DE UM TUMOR, COMPOSIÇÃO E KIT

Em ExigênciaInvention PatentPCT · US2020021570

Application data

Number

112021017774

Type

Invention Patent

Filing

03/06/2020

Publication

11/16/2021

PCT

US2020021570

Progress at the INPI

Technical opinion to answer
  1. Filing03/06/20
  2. Publication11/16/21
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 05/26/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

CEND THERAPEUTICS, INC.

US

Inventors

E. R. (pessoa física)

US

H. J. (pessoa física)

US

Technical data

IPC Classification

Priority claims

US

62/815,917 · 03/08/2019

Abstract

DOSE BAIXA DE CITOCINA COADMINISTRADA COM IRGD PARA TRATAR CÂNCER. Métodos e composições compreendendo iRGD coadministrado com citocinas para tratar câncer são fornecidos.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Parecer de pré-exame

#6.23

05/26/2026

RPI 2890

Notificação de entrada na fase nacional - PCT

#1.3

11/16/2021

RPI 2654

Alteração de dados cadastrais

#1.1

09/21/2021

RPI 2646

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.